Arvinas, Inc (ARVN)
NASDAQ · Manufacturing · Pharmaceutical preparations
ARVN price, last 12 months
Key stats
- Previous close
- $6.77
- Open
- $6.78
- Day range
- $6.52 – $6.86
- 52-week range
- $6.33 – $14.51
- Volume
- 843.6K
- Avg volume (20 days)
- 1M
- Market cap
- $446.6M
Performance
Technicals and fundamentals
About Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $446.6M